Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga …
Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), …
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While …
Just under a week after losing a key court trial that would have protected its blockbuster drug Wegovy (semaglutide) from …
Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen …
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular …
Merck & Co (MSD) has joined fellow big pharma companies in looking to redirect cash, as the drugmaker revealed plans …
South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn …
Following the pharmaceutical giant’s intentions to home in on its immunology portfolio, Bristol Myers Squibb (BMS) has teamed up with …
The European Union (EU) will pay the US a tariff rate of 15% for pharmaceuticals as part of a new …
Alfasigma plans to engage with regulators to seek approval for Jyseleca (filgotinib) in active axial spondyloarthritis (axSpA) following a successful …
Re-Vana Therapeutics, a spin-out from Queen’s University, has entered a partnership and licence agreement with Boehringer Ingelheim for the development …
After two weeks in the regulatory wringer, Sarepta Therapeutics has been given clearance to continue shipments of its Duchenne muscular …
The US Food and Drug Administration (FDA) has granted approval for Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH), a …
The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) …
